Clinical Trial Update: Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth [Phase 1]

View source ↗

Summary

Phase 1 study evaluating intravitreal ranibizumab for macular telangiectasia without neovascularization has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Macular Telangiectasia | Phase 1 | Status: COMPLETED